Image of Clinical Pharmacology of Eptifibatide

LITERATURE

Clinical Pharmacology of Eptifibatide


Activation of receptor function of platelet membrane
glycoprotein (GP) IIb-IIIa leads to the binding of fibrinogen and is the final common pathway to platelet aggregation. Platelet aggregates provide the structural basis
for coronary thrombosis, a major cause of ischemic
heart disease. GP IIb-IIIa has a narrow tissue distribution, being found only on platelets and their progenitors,
and inhibition of its receptor function has emerged as a
promising new therapeutic strategy for management of
acute ischemic coronary syndromes and acute ischemic
complications of percutaneous coronary interventions.
Eptifibatide (INTEGRILIN) is a cyclic heptapeptide inhibitor of GP IIb-IIIa, with an active pharmacophore that is
derived from the structure of barbourin, a GP IIb-IIIa
inhibitor from the venom of the southeastern pigmy
rattlesnake. Like barbourin, eptifibatide is a specific and
robust inhibitor of the GP IIb-IIIa receptor function, having a low affinity for other integrins and strongly preventing platelet aggregation


Availability

Ebatid-003Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Am J Cardiol 1997;80(4A):11B–20B
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous